Reports Q4 revenue $7.753M, consensus $1.99M. "The past year for Aclaris was marked by tremendous execution across our organization notably highlighted by our clinical development programs and our proprietary kinase-focused drug discovery platform," stated Doug Manion, M.D., Chief Executive Officer of Aclaris. "We enter 2023 well positioned to capitalize on that momentum with multiple data read-outs expected, beginning with top line data from the Phase 2a trial of zunsemetinib in hidradenitis suppurativa next month." Continued Dr. Manion, "In addition to the enthusiasm related to our upcoming development-stage milestones, we also continue to benefit from the output of our KINect discovery engine, and the ability to identify novel development candidates, which we believe will not only position us to continue to build long-term shareholder value, but also enable us to further fulfill our mission of delivering new therapeutic options for patients."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACRS:
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
- Stifel biotechnology analyst to hold an analyst/industry conference call
- Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
- Fly Insider Express, ServiceNow among week’s notable insider trades
- Aclaris Therapeutics provides corporate outlook for 2023